Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 5/2006

01.05.2006 | Therapy In Practice

Management of Epilepsy in Women of Childbearing Age

Practical Recommendations

verfasst von: Dr Barbara Tettenborn

Erschienen in: CNS Drugs | Ausgabe 5/2006

Einloggen, um Zugang zu erhalten

Abstract

Women with epilepsy should not be discouraged from becoming pregnant as the likelihood of having a healthy baby is very high. However, in such women, early and individualised counselling about pregnancy and contraception is essential. Ideally, pregnancies should be planned, folic acid (5 mg/day) given and antiepileptic drug (AED) treatment optimised well before conception to ensure that the lowest dosage that controls seizures is administered. When initiating AEDs in a woman of childbearing age, the most appropriate drug for the seizure type and syndrome should be chosen, although it is preferable to avoid valproate, because of a possible elevated risk of fetal malformations, when equi-effective agents are available for a given syndrome.
In women who become pregnant while taking AEDs, fetal monitoring should include high-resolution ultrasonography before week 20 and measurement of serum α-fetoprotein levels. Amniocentesis is not routinely indicated. The measurement of blood concentrations of AEDs can be useful to ensure that the lowest possible maintenance dosage is being used, especially for those drugs whose pharmacokinetics are likely to change during pregnancy. Breastfeeding should be encouraged whatever the treatment administered.
Literatur
1.
Cockrell OC, Eckle I, Goodridge DM, et al. Epilepsy in a population of 6000 re-examined: secular trends in first attendance rates, prevalence, and prognosis. J Neurol Neurosurg Psychiatry 1996; 58: 570–6CrossRef
2.
Sander JW, Shorvon SD. Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry 1996; 61: 433–43PubMedCrossRef
3.
Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc 1996; 71: 576–86PubMedCrossRef
4.
Wallace H, Shorvon S, Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2 052 922 and age-specific fertility rates of women with epilepsy. Lancet 1998; 352: 1970–3PubMedCrossRef
5.
MacDonald BK, Cockerell OC, Sander JW, et al. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000; 123: 665–76PubMedCrossRef
6.
Kotsopoulos IA, van Merode T, Kessels FG, et al. Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia 2002; 43: 1402–9PubMedCrossRef
7.
Loiseau P. Human absence epilepsies. J Neural Transm Suppl 1992; 35: 1–6PubMed
8.
The RESt-1 Group. Social aspects of epilepsy in the adult in seven European countries. Epilepsia 2000; 41(8): 998–1004CrossRef
9.
Callaghan N, Crowley M, Goggin T. Epilepsy and employment, marital, education and social status. Ir Med J 1992 Mar; 85(1): 17–9PubMed
10.
Jalava M, Sillanpaa M. Reproductive activity and offspring health of young adults with childhood-onset epilepsy: a controlled study. Epilepsia 1997; 38: 532–40PubMedCrossRef
11.
Wakamoto H, Nagao H, Hayashi M, et al. Long-term medical, educational, and social prognoses of childhood-onset epilepsy: a population-based study in a rural district of Japan. Brain Dev 2000; 22: 246–55PubMedCrossRef
12.
Jacoby A, Baker GA, Steen N, et al. The clinical course of epilepsy and its psychosocial correlates: findings from a U.K. community study. Epilepsia. 1996; 37(2): 148–61PubMedCrossRef
13.
Schupf N, Ottman R. Likelihood of pregnancy in individuals with idiopathic/cryptogenic epilepsy: social and biologic influences. Epilepsia 1994; 35: 750–6PubMedCrossRef
14.
Crawford P, Hudson S. Understanding the information needs of women with epilepsy at different lifestages: results of the ‘Ideal World’ survey. Seizure 2003; 12: 502–7PubMedCrossRef
15.
Webber MP, Hauser WA, Ottman R, et al. Fertility in persons with epilepsy: 1935–1974. Epilepsia 1986; 27: 746–52PubMedCrossRef
16.
Olafsson E, Hauser WA, Gudmundsson G. Fertility in patients with epilepsy: a population-based study. Neurology 1998; 51: 71–3PubMedCrossRef
17.
Artama M, Isojärvi JI, Raitanen J, et al. Birth rate among patients with epilepsy: a nationwide population-based cohort study in Finland. Am J Epidemiol 2004; 159: 1057–63PubMedCrossRef
18.
Royal College of Physicians. Adults with poorly controlled epilepsy: clinical guidelines for treatment and practical tools for aiding epilepsy management. London: Royal College of Physicians, 1997
19.
Herzog AG, Seibel MM, Schomer DL, et al. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986; 43: 341–6PubMedCrossRef
20.
Morrell MJ. Epilepsy in women: the science of why it is special. Neurology 1999; 53(4 Suppl. 1): S42–8PubMed
21.
Murialdo G, Galimberti CA, Magri F, et al. Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy. J Endocrinol Invest 1997; 20: 519–26PubMed
22.
Clayton RN, Ogden V, Hodgkinson J, et al. How common are polycystic ovaries in normal women and what is their significance for the fertility of the population? Clin Endocrinol (Oxf) 1992; 37: 127–34CrossRef
23.
Farquhar CM, Birdsall M, Manning P, et al. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. Aust N Z J Obstet Gynaecol 1994; 34: 67–72PubMedCrossRef
24.
Genton P, Bauer J, Duncan S, et al. On the association between valproate and polycystic ovary syndrome. Epilepsia 2001; 42: 295–304PubMedCrossRef
25.
Isojärvi JI, Tauboll E, Tapanainen JS, et al. On the association between valproate and polycystic ovary syndrome: a response and an alternative view. Epilepsia 2001; 42: 305–10PubMedCrossRef
26.
Isojärvi JI, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329: 1383–8PubMedCrossRef
27.
Isojärvi JI. Reproductive dysfunction in women with epilepsy. Neurology 2003; 61(6 Suppl. 2): S27–34PubMedCrossRef
28.
Murialdo G, Galimberti CA, Gianelli MV, et al. Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol 1998; 21: 52–8PubMed
29.
Luef G, Abraham I, Haslinger M, et al. Polycystic ovaries, obesity and insulin resistance in women with epilepsy: a comparative study of carbamazepine and valproic acid in 105 women. J Neurol 2002; 249: 835–41PubMedCrossRef
30.
Bauer J, Jarre A, Klingmuller D, et al. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res 2000; 41: 163–7PubMedCrossRef
31.
Herzog AG, Schachter SC. Valproate and the polycystic ovarian syndrome: final thoughts. Epilepsia 2001; 42: 311–5PubMedCrossRef
32.
Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected Black and White women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078–82PubMedCrossRef
33.
Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745–9PubMedCrossRef
34.
Herzog AG, Seibel MM, Schomer D, et al. Temporal lobe epilepsy: an extrahypothalamic pathogenesis for polycystic ovarian syndrome? Neurology 1984; 34: 1389–93PubMedCrossRef
35.
Bilo L, Meo R, Nappi C, et al. Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia 1988; 29: 612–9PubMedCrossRef
36.
Bilo L, Meo R, Valentino R, et al. Characterization of reproductive endocrine disorders in women with epilepsy. J Clin Endocrinol Metab 2001; 86: 2950–6PubMedCrossRef
37.
Isojärvi JL, Touboll E, Herzog AG. Effect of antiepileptic drugs on reproductive endocrine function in individuals wtih epilepsy. CNS Drugs 2005; 19: 207–23PubMedCrossRef
38.
Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saf 2001; 24: 969–78PubMedCrossRef
39.
Pasquali R, Casimirri F, Vicennati V. Weight control and its beneficial effect on fertility in women with obesity and polycystic ovary syndrome. Hum Reprod 1997; 12Suppl. 1: 82–7PubMedCrossRef
40.
Bauer J, Isojärvi JI, Herzog AG, et al. Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management. J Neurol Neurosurg Psychiatry 2002; 73: 121–5PubMedCrossRef
41.
Patsalos PN. Pharmacokinetic and pharmacodynamic interactions: principles and interpretative pitfalls. Epileptologia 1998; 6: 9–19
42.
Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002; 16: 263–72PubMedCrossRef
43.
Sabers A, Buchholt JM, Uldall P, et al. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2001; 47: 151–4PubMedCrossRef
44.
Sabers A, Ohman I, Christensen J, et al. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003; 61: 570–1PubMedCrossRef
45.
Crawford P, Chadwick DJ, Martin C, et al. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 1990; 30: 892–6PubMedCrossRef
46.
Eldon MA, Underwood BA, Randinitis EJ, et al. Gabapentin does not interact with a contraceptive regimen of norethindrone acetate and ethinyl estradiol. Neurology 1998; 50: 1146–8PubMedCrossRef
47.
Ragueneau-Majlessi I, Levy RH, Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia 2002; 43: 697–702PubMedCrossRef
48.
Fattore C, Cipolla G, Gatti G, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999; 40: 783–7PubMedCrossRef
49.
Back DJ, Bates M, Bowden A, et al. The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. Contraception 1980; 22: 495–503PubMedCrossRef
50.
Coulam CB, Annegers JF. Do anticonvulsants reduce the efficacy of oral contraceptives? Epilepsia 1979; 20: 519–25PubMedCrossRef
51.
52.
Doose DR, Wang SS, Padmanabhan M, et al. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia 2003; 44: 540–9PubMedCrossRef
53.
Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 2004; 43: 763–80PubMedCrossRef
54.
Crawford P, Chadwick D, Cleland P, et al. The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. Contraception 1986; 33: 23–9PubMedCrossRef
55.
Shorvon SD, Tallis RC, Wallace HK. Antiepileptic drugs: coprescription of proconvulsant drugs and oral contraceptives: a national study of antiepileptic drug prescribing practice. J Neurol Neurosurg Psychiatry 2002; 72: 114–5PubMedCrossRef
56.
57.
Fried S, Kozer E, Nulman I, et al. Malformation rates in children of women with untreated epilepsy: a meta-analysis. Drug Saf 2004; 27: 197–202PubMedCrossRef
58.
MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338: 131–7CrossRef
59.
Tettenborn B, Genton P, Polson D. Epilepsy and women’s issues: an update. Epileptic Disord 2002; 4Suppl. 2: S23–31PubMed
60.
Fairgrieve SD, Jackson M, Jonas P, et al. Population based, prospective study of the care of women with epilepsy in pregnancy. BMJ 2000; 321: 674–5PubMedCrossRef
61.
Betts T, Fox C. Proactive pre-conception counselling for women with epilepsy: is it effective? Seizure 1999; 8: 322–7PubMedCrossRef
62.
Beghi E, Roncolato M, Visonà G. Depression and quality of life in women with epilepsy of childbearing age. Epilepsia 2004; 45: 64–70PubMedCrossRef
63.
Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy. Neurology 1992; 42Suppl. 5: 149–60PubMed
64.
Yerby MS, Kaplan P and Tran T. Risks and management of pregnancy in women with epilepsy. Cleve Clin J Med 2004; 71(2): S25–37PubMedCrossRef
65.
66.
Perucca E, Crema A. Plasma protein binding of drugs in pregnancy. Clin Pharmacokinet 1982; 7: 336–52PubMedCrossRef
67.
Yerby MS, Friel PN, McCormick K. Antiepileptic drug disposition during pregnancy. Neurology 1992; 42(4 Suppl. 5): 12–6PubMed
68.
Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 433–43PubMedCrossRef
69.
Tran TA, Leppik IE, Blesi K, et al. Lamotrigine clearance during pregnancy. Neurology 2002; 59: 251–5PubMedCrossRef
70.
de Haan GJ, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004; 63: 571–3PubMedCrossRef
71.
Tomson T, Perucca E, Battino D. Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia 2004; 45: 1171–5PubMedCrossRef
72.
O’Brien MD, Gilmour-White SK. Management of epilepsy in women. Postgrad Med J 2005; 81: 278–85PubMedCrossRef
73.
Quality Standards Committee of the American Academy of Neurology. Practice parameter: management issues for women with epilepsy (summary statement). Neurology 1998; 51: 944–8CrossRef
74.
Crawford P, Appleton R, Betts T, et al. Best practice guidelines for the management of women with epilepsy. The Women with Epilepsy Guidelines Development Group. Seizure 1999; 8: 201–17
75.
Perucca E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol 2005; 4: 781–6PubMedCrossRef
76.
77.
Lindhout D, Omtzigt JG. Pregnancy and the risk of teratogenicity. Epilepsia 1992; 33Suppl. 4: S41–8PubMedCrossRef
78.
Kaneko S, Otani K, Hirano T, et al. Teratogenicity of antiepileptic drugs: is the prevention possible? Jpn Psychiatry Neurol 1991 Jun; 45(2): 478–81
79.
Nulman I, Scolnik D, Chitayat D, et al. Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. Am J Med Genet 1997; 68: 18–24PubMedCrossRef
80.
Pearlman MD, Tintinalli JE, Lorenz RP. Blunt trauma during pregnancy. N Engl J Med 1990; 323: 1609–13PubMedCrossRef
81.
Cunnington M, Tennis P, International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Lamotrigine and the risk of malformations in pregnancy. Neurology 2005; 64: 955–60PubMedCrossRef
82.
Montouris G. Safety of the newer antiepileptic drug oxcarbazepine during pregnancy. Curr Med Res Opin 2005; 21: 693–701PubMedCrossRef
83.
Dravet C, Julian C, Legras C, et al. Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: a French prospective cohort study. Neurology 1992; 42Suppl. 5: 75–82PubMed
84.
Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344: 1132–8PubMedCrossRef
85.
Samrén EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997; 38: 981–90PubMedCrossRef
86.
Canger R, Battino D, Canevini MP, et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia 1999; 40: 1231–6PubMedCrossRef
87.
Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999; 33: 145–58PubMedCrossRef
88.
Samrén EB, van Duijn CM, Christiaens GC, et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999; 46: 739–46PubMedCrossRef
89.
Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 2003; 60: 575–9PubMedCrossRef
90.
Holmes LB, Wyszynski DF. North American Antiepileptic Drug Pregnancy Registry. Epilepsia 2004; 45: 1465PubMedCrossRef
91.
Tomson T, Battino D, Bonizzoni E, et al. EURAP: an international registry of antiepileptic drugs and pregnancy. Epilepsia 2004; 45: 1463–4PubMedCrossRef
92.
Vajda F, Lander C, O’Brien T, et al. Australian Pregnancy Registry of women taking antiepileptic drugs. Epilepsia 2004; 45: 1466PubMedCrossRef
93.
Russell AJ, Craig JJ, Morrison P, et al. UK epilepsy and pregnancy group. Epilepsia 2004; 45: 1467PubMedCrossRef
94.
Morrow JI, Craig JJ, Russell AJC, et al. Which antiepileptic drugs are safest in pregnancy? Epilepsia 2004; 44Suppl. 8: P096
95.
Craig JJ, Russell A, Parsons L, et al. The UK Epilepsy and Pregnancy Register: update of results 1996–2003. Epilepsia 2004; 45Suppl. 7: 229
96.
Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 2004; 61: 673–8PubMedCrossRef
97.
Holmes LB. The teratogenicity of anticonvulsant drugs: a progress report. J Med Genet 2002; 39: 245–7PubMedCrossRef
98.
Tennis P, Eldridge RR, on behalf of International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Preliminary results on pregnancy outcomes in women using lamotrigine. Epilepsia 2002; 43: 1161–7PubMedCrossRef
99.
Cunnington MC. The International Lamotrigine Pregnancy Registry update for The Epilepsy Foundation. Epilepsia 2004; 45: 1468PubMedCrossRef
100.
Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 2004; 93: 174–6PubMedCrossRef
101.
Fishman MA. Birth defects and supplemental vitamins. Curr Treat Options Neurol 2000; 2: 117–22PubMedCrossRef
102.
Hernandez-Diaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343: 1608–14PubMedCrossRef
103.
Ogawa Y, Kaneko S, Otani K, et al. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. Epilepsy Res 1991; 8: 75–8PubMedCrossRef
104.
Dansky LV, Andermann E, Andermann F. Marriage and fertility in epileptic patients. Epilepsia 1980; 21: 261–71PubMedCrossRef
105.
Yerby MS. Management issues for women with epilepsy: neural tube defects and folic acid supplementation. Neurology 2003; 61Suppl. 2: S23–6PubMedCrossRef
106.
Adab N, Jacoby A, Smith D, et al. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2001; 70: 15–21PubMedCrossRef
107.
Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004; 75: 1575–83PubMedCrossRef
108.
Gaily E, Kantola-Sorsa E, Hiilesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004; 62: 28–32PubMedCrossRef
109.
Cornelissen M, Steegers-Theunissen R, Kollee L, et al. Increased incidence of neonatal vitamin K deficiency resulting from maternal anticonvulsant therapy. Am J Obstet Gynecol 1993; 168: 923–8PubMed
110.
Moslet U, Hansen ES. A review of vitamin K, epilepsy and pregnancy. Acta Neurol Scand 1992 Jan; 85(1): 39–43PubMedCrossRef
111.
Cornelissen M, Steegers-Theunissen R, Kollee L, et al. Supplementation of vitamin K in pregnant women receiving anticonvulsant therapy prevents neonatal vitamin K deficiency. Am J Obstet Gynecol 1993; 168: 884–48PubMed
112.
Autret-Leca E, Jonville-Bera AP. Vitamin K in neonates: how to administer, when and to whom. Paediatr Drugs 2001; 3: 1–8PubMedCrossRef
113.
114.
Kaaja E, Kaaja R, Matila R, et al. Enzyme-inducing antiepileptic drugs in pregnancy and the risk of bleeding in the neonate. Neurology 2002; 58: 549–53PubMedCrossRef
115.
Choulika S, Grabowski E, Holmes LB. Is antenatal vitamin K prophylaxis needed for pregnant women taking anticonvulsants? Am J Obstet Gynecol 2004; 190: 882–3PubMedCrossRef
116.
Malone FD, D’Alton ME. Drugs in pregnancy: anticonvulsants. Semin Perinatol 1997; 21: 114–23PubMedCrossRef
117.
118.
Janz D, Dam M, Richens A. Epilepsy, pregnancy and the child. New York: Raven, 1982
119.
Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology 2003; 61(6 Suppl. 2): S35–42PubMedCrossRef
120.
Bulau P, Paar WD, von Unruh GE. Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother. Eur J Clin Pharmacol 1988; 34: 311–3PubMedCrossRef
Metadaten
Titel
Management of Epilepsy in Women of Childbearing Age
Practical Recommendations
verfasst von
Dr Barbara Tettenborn
Publikationsdatum
01.05.2006
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 5/2006
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200620050-00003

Weitere Artikel der Ausgabe 5/2006

CNS Drugs 5/2006 Zur Ausgabe

Adis Drug Profile

Zolpidem Extended-Release

Adis Spotlight

Spotlight on Quetiapine in Acute Mania and Depression Associated with Bipolar Disorder

Adis Drug Profile

Zolpidem Extended-Release

Adis Drug Profile

Zolpidem Extended-Release

Original Research Article

Cardiovascular Effects and Risk of Syncope Related to Donepezil in Patients with Alzheimer’s Disease

Leading Article

Role of Melatonin in the Pathophysiology of Migraine

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise